11 September 2020 : Clinical Research
A Retrospective Study of the C-Reactive Protein to Lymphocyte Ratio and Disease Severity in 108 Patients with Early COVID-19 Pneumonia from January to March 2020 in Wuhan, ChinaMiao Yang1ACDEG, Xiaoping Chen2ABCF*, Yancheng Xu1ADFG
Med Sci Monit 2020; 26:e926393
BACKGROUND: The aim of this study was to determine the effect of C-reactive protein (CRP), lymphocytes (LYM), and the ratio of CRP to LYM (CRP/LYM) on assessing the prognosis of COVID-19 severity at early stages of disease.
MATERIAL AND METHODS: A total of 108 hospitalized patients diagnosed with COVID-19 in Zhongnan Hospital of Wuhan University from January 17, 2020 to March 12, 2020 were enrolled. Data of demographic parameters, clinical characteristics, laboratory indicators, clinical manifestation, and outcome of disease were collected. The patients were divided into a severe group and a non-severe group according to diagnosis and classification, which followed the guidelines and management of the Chinese National Health Council COVID-19. The receiver-operating characteristic (ROC) analysis and comparison of ROC curves were used for the laboratory findings for assessment of COVID-19 severity.
RESULTS: Of the 108 patients, 42 patients (38.9%) were male and 24 patients (22.2%) were considered severe cases, with the mean age of 51.0 years old. Males and patients with comorbidities were more likely to become severe cases. CRP increased and LYM decreased in the severe group.The results for the areas under the curve (AUC) of CRP/LYM and CRP used to assess severe COVID-19 were 0.787 (95% CI 0.698–0.860, P<0.0001) and 0.781 (95% CI 0.693–0.856, P<0.0001), respectively; both results were better than that of LYM. The associated criterion value of CRP/LYM was calculated, with an excellent sensitivity of 95.83%.
CONCLUSIONS: The effect of CRP/LYM and CRP on the assessment for severe COVID-19 may be superior to LYM alone. CRP/LYM is a highly sensitive indicator to assess the severity of COVID-19 in the early stage of disease.
Keywords: Coronavirus, Inflammation, Lymphocytes, Risk Adjustment
18 October 2021 : EditorialEditorial: Global Initiatives Support the Use and Regulation of Digital Health Technology During the COVID-19 Pandemic
Med Sci Monit 2021; 27:e935123
20 October 2021 : EditorialEditorial: The 2021 European Society of Cardiology (ESC) Guidelines on the Real-World Prevention of Atheros...
Med Sci Monit In Press; DOI: 10.12659/MSM.935172
22 October 2021 : Clinical ResearchA Novel Method for the Production of an Autologous Anti-Inflammatory and Anti-Catabolic Product (Cytorich) ...
Med Sci Monit In Press; DOI: 10.12659/MSM.934365
11 October 2021 : Clinical ResearchClinical Features and Temporal Lung Radiographic Changes in 25 Patients Recovering from COVID-19 Pneumonia:...
Med Sci Monit In Press; DOI: 10.12659/MSM.933381
22 Oct 2021 : Clinical ResearchUlnar Groove Plasty Guided by a 3D Printing Technique for Moderate to Severe Cubital Tunnel Syndrome Caused...
Med Sci Monit In Press; DOI: 10.12659/MSM.933775
22 Oct 2021 : Clinical ResearchTotal Fluoroscopy Time Reduction During Ultrasound- and Fluoroscopy-Guided Percutaneous Transhepatic Biliar...
Med Sci Monit In Press; DOI: 10.12659/MSM.933889
22 Oct 2021 : Clinical ResearchCorrelation Between Severity of Illness and Levels of Free Triiodothyronine, Interleukin-6, and Interleukin...
Med Sci Monit In Press; DOI: 10.12659/MSM.933230
Most Viewed Current Articles
20 Mar 2020 : Clinical ResearchSocial Capital and Sleep Quality in Individuals Who Self-Isolated for 14 Days During the Coronavirus Diseas...
Med Sci Monit 2020; 26:e923921
15 Apr 2020 : Clinical ResearchPsychological Impact and Coping Strategies of Frontline Medical Staff in Hunan Between January and March 20...
Med Sci Monit 2020; 26:e924171
05 May 2020 : Review articleAn Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development
Med Sci Monit 2020; 26:e924700